Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Presently amended) ~~The present invention provides a~~ A compound of formula (I), or a pharmaceutically acceptable salt thereof, or solvate thereof, or a solvate of a salt thereof:



(I)

wherein

Z is CR^4R^5, ~~C(O) or CR^4R^5~~ Z^1, wherein R^4 and R^5 are CH_2;

~~Z^1 is C_{1-4} alkylene, C_{2-4} alkenylene or C(O)NH;~~

~~R^1 represents a C_1, C_{12} alkyl group optionally substituted by one or more substituents independently selected from cyano, hydroxyl, C_1, C_6 alkoxy, C_1, C_6 alkylthio, C_{3-7} cycloalkyl, C_1-C_6 alkoxycarbonyl and phenyl (itself optionally substituted by one or more of halogen, nitro, cyano, C_1, C_6 alkyl, C_1, C_6 haloalkyl, phenyl(C_1, C_6 alkyl), C_1, C_6 alkoxy, C_1, C_6 haloalkoxy, $S(O)_2$(C_1, C_6 alkyl), C(O)NH_2, carboxy or C_1, C_6 alkoxycarbonyl); or~~

~~R^1 represents C_2-C_6 alkenyl optionally substituted by phenyl (itself optionally substituted by one or more of halogen, nitro, cyano, C_1-C_6 alkyl, C_1-C_6 haloalkyl, phenyl(C_1-C_6 alkyl), C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, $S(O)_2$(C_1-C_6 alkyl), C(O)NH_2, carboxy or C_1-C_6 alkoxycarbonyl); or~~

R^1 represents a 3- to 14-membered saturated or unsaturated ring system which ~~optionally~~ comprises up to two ring carbon atoms that form carbonyl groups and which ~~optionally~~ further comprises up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, wherein the ring system is optionally substituted by one or more substituents independently selected from: halogen, cyano, nitro, oxo, hydroxyl, C_1-C_8 alkyl, C_1-C_6 hydroxyalkyl, C_1-C_6 haloalkyl, C_{1-6} alkoxy(C_1-C_6 alkyl), C_3-C_7 cycloalkyl(C_1-C_6 alkyl), C_1-C_6 alkylthio(C_1-C_6 alkyl),

C_1-C_6 alkylcarbonyloxy(C_1-C_6 alkyl), C_1-C_6 alkylS(O)$_2$(C_1-C_6 alkyl), aryl(C_1-C_6 alkyl), heterocyclyl(C_1-C_6 alkyl), arylS(O)$_2$(C_1-C_6 alkyl), heterocyclylS(O)$_2$(C_1-C_6 alkyl), aryl(C_1-C_6 alkyl)S(O)$_2$, heterocyclyl(C_1-C_6 alkyl)S(O)$_2$, C_2-C_6 alkenyl, C_1-C_6 alkoxy, carboxy-substituted C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 hydroxyalkoxy, C_1-C_6 alkylcarboxy-substituted C_1-C_6 alkoxy, aryloxy, heterocyclyloxy, C_1-C_6 alkylthio, C_3-C_7 cycloalkyl(C_1-C_6 alkylthio), C_2-C_6 alkynylthio, C_1-C_6 alkylcarbonylamino, C_1-C_6 haloalkylcarbonylamino, SO_3H, -NR^7R^8, -$C(O)NR^{23}R^{24}$, $S(O)_2NR^{18}R^{19}$, $S(O)_2R^{20}$, $R^{25}C(O)$, carboxyl, C_1-C_6 alkoxycarbonyl, aryl and heterocyclyl; wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by one or more of halogen, oxo, hydroxy, nitro, cyano, C_1-C_6 alkyl, C_1-C_6 haloalkyl, phenyl(C_1-C_6 alkyl), C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, $S(O)_2$(C_1-C_6 alkyl), $C(O)NH_2$, carboxy or C_1-C_6 alkoxycarbonyl;

m is 0~~ or 1~~;

~~Q represents an oxygen or sulphur atom or a group NR^9, C(O), C(O)NR^9, $NR^9C(O)$ or CH=CH;~~

n is ~~0, 1, 2, 3, 4, 5 or 6 provided that when n is 0, then m is 0~~;

each R^2 and R^3 independently represents a hydrogen atom or a C_1-C_4 alkyl group, or $(CR^2R^3)_n$ represents C_3-C_7 cycloalkyl optionally substituted by C_1-C_4 alkyl;

T represents a group ~~NR^{16}~~, $C(O)NR^{10}$~~, $NR^{11}C(O)NR^{10}$ or $C(O)NR^{10}NR^{11}$~~, wherein R^{10} is H;

X^1, X^2, X^3 and X^4 are, independently, CH_2~~, CHR^{12} (wherein each R^{12} is, independently, C_1-C_4 alkyl or C_3-C_7 cycloalkyl(C_1-C_4 alkyl)) or C=O; or, when they are CHR^{12}, the R^{12} groups of X^1 and X^2 or X^1, or, X^2 and X^3 or X^4 join to form a two or three atom chain which is CH_2CH_2, $CH_2CH_2CH_2$, CH_2OCH_2 or CH_2SCH_2; provided always that at least two of X^1, X^2, X^3 and X^4 are CH_2~~;

R^4 and R^5 each independently represent a hydrogen atom or a C_1-C_4 alkyl group;

R^6 is ~~aryl or heterocyclyl~~phenyl, ~~both~~ optionally substituted by one or more of: halogen, cyano, nitro, oxo, hydroxyl, C_1-C_8 alkyl, C_1-C_6 hydroxyalkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy(C_1-C_6 alkyl), C_3-C_7 cycloalkyl(C_1-C_6 alkyl), C_1-C_6 alkylthio(C_1-C_6 alkyl), C_1-C_6 alkylcarbonyloxy(C_1-C_6 alkyl), C_1-C_6 alkylS(O)$_2$(C_1-C_6 alkyl), aryl(C_1-C_6 alkyl), heterocyclyl(C_1-C_6 alkyl), arylS(O)$_2$(C_1-C_6 alkyl), heterocyclylS(O)$_2$(C_1-C_6 alkyl), aryl(C_1-C_6 alkyl)S(O)$_2$, heterocyclyl(C_1-C_6

alkyl)$S(O)_2$, C_2-C_6 alkenyl, C_1-C_6 alkoxy, carboxy-substituted C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 hydroxyalkoxy, C_1-C_6 alkylcarboxy-substituted C_1-C_6 alkoxy, aryloxy, heterocyclyloxy, C_1-C_6 alkylthio, C_3-C_7 cycloalkyl(C_1-C_6 alkylthio), C_3-C_6 alkynylthio, C_1-C_6 alkylcarbonylamino, C_1-C_6 haloalkylcarbonylamino, SO_3H, $-NR^{16}R^{17}$, $-C(O)NR^{21}R^{22}$, $S(O)_2NR^{13}R^{14}$, $S(O)_2R^{15}$, $R^{26}C(O)$, carboxyl, C_1-C_6 alkoxycarbonyl, aryl and heterocyclyl; wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by one or more of halogen, nitro, cyano, C_1-C_6 alkyl, C_1-C_6 haloalkyl, phenyl(C_1-C_6 alkyl), C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, $S(O)_2$(C_1-C_6 alkyl), $C(O)NH_2$, carboxy or C_1-C_6 alkoxycarbonyl;

R^7, R^8, R^9, R^{10}, R^{11}, R^{13}, R^{14}, R^{16}, R^{17}, R^{18}, R^{19}, R^{21}, R^{22}, R^{23} and R^{24} are, independently hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkyl(C_1-C_4 alkyl) or phenyl(C_1-C_6 alkyl); and,

R^{15} and R^{20} are, independently, C_1-C_6 alkyl, C_1-C_6 hydroxyalkyl, C_3-C_6 cycloalkyl, C_3-C_7 cycloalkyl(C_1-C_4 alkyl) or C_1-C_6 alkyl optionally substituted by phenyl;

R^{25} and R^{26} are, independently, C_1-C_6 alkyl or phenyl (optionally substituted by one or more of halogen, nitro, cyano, C_1-C_6 alkyl, C_1-C_6 haloalkyl, phenyl(C_1-C_6 alkyl), C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, $S(O)_2$(C_1-C_6 alkyl), $C(O)NH_2$, carboxy or C_1-C_6 alkoxycarbonyl);

~~or a pharmaceutically acceptable salt thereof, or solvate thereof, or a solvate of a salt thereof; provided that when T is $C(O)NR^{19}$ and R^4 is optionally substituted phenyl then n is not 0.~~

2-4. (Cancelled)

5. (Original) A compound as defined in any one of Examples 1 to 416.

6. (Presently amended) A process for the preparation of a compound of formula (I) as defined in claim 1 which comprises:

~~(a) when n is at least 1, the CR^2R^3 group attached directly to T is CHR^2 and T is NR^{19}, reacting a compound of general formula~~

Applicant : Stephen Thom et al.
Serial No. : 10/069,215
Filed : February 22, 2002
Page : 5 of 11

Attorney's Docket No.: 06275-244US1 / A 2214-1P US



(II)

wherein n' is 0 or an integer from 1 to 3 and R^1, R^2, R^3, m and Q are as defined in formula (I), with a compound of general formula



(III)

or a salt thereof, wherein X^1, X^2, X^3, X^4, Z, R^6 and R^{10} are as defined in formula (I), in the presence of a reducing agent; or

(b) when n is at least 1, the CR^2R^3 group attached directly to T is $C(C_1$-C_4 alkyl)$_2$ and T is NR^{10}, reacting a compound of general formula



(IV)

wherein n' is 0 or an integer from 1 to 3, $R^{2'}$ and $R^{3'}$ each independently represent a C_1-C_4 alkyl group, and R^1, R^2, R^3, R^{10}, m and Q are as defined in formula (I), with a compound of general formula



(V)

wherein X^1, X^2, X^3, X^4, Z and R^6 are as defined in formula (I), in the presence of a reducing agent; or

(ea) when T is $C(O)NR^{10}$, reacting a compound of general formula



(VI)

wherein R^1, R^2, R^3, Q, m and n are as defined in formula (I), with a compound of formula (III)



(III)

wherein X^1, X^2, X^3, X^4, Z, R^6 and R^{10} are as defined in formula (I),
or a salt thereof as defined in (a) above; or

~~(d) when m is 1 and Q is NR^9, reacting a compound of general formula (VII), R^1-L^+, wherein L^+ represents a leaving group (e.g. a halogen atom) and R^1 is as defined in formula (I), with a compound of general formula~~



~~(VIII)~~

~~or a salt thereof, wherein n, T, X^1, X^2, X^3, X^4, Z, R^3, R^5, R^6 and R^9 are as defined in formula (I); or~~

(eb) when at least one of R^4 and R^5 represents a hydrogen atom, reacting a compound of general formula



(IX)

or a salt thereof, wherein R^1, R^2, R^3, Q, m, n, X^1, X^2, X^3, X^4 and T are as defined in formula (I), with a compound of general formula (X), R^6 - C(O) - R^{20}, wherein R^{20} represents a hydrogen atom or a C_1-C_4 alkyl group and R^6 is as defined in formula (I), in the presence of a reducing agent; or

(~~c~~f) reacting a compound of formula (IX) as defined in (~~b~~)(b) above, with a compound of general formula

(XI)

wherein L^2 represents a leaving group (e.g. a halogen atom) and Z and R^6 are as defined in formula (I); ~~or~~

~~(g) when T is NR^{10}, reacting a compound of general formula~~



~~(XII)~~

~~wherein L^2 represents a leaving group (e.g. a halogen atom) and R^1, R^2, R^3, m, n and Q are as defined in formula (I), with a compound of formula (III) or a salt thereof as defined in (a) above; or~~

~~(h) when T is $NHC(O)NR^{10}$, reacting a compound of general formula~~

~~(XIII)~~

~~wherein R^1, R^2, R^3, Q, m and n are as defined in formula (I), with a compound of formula (III) or a salt thereof as defined in (a) above; or~~

~~(i) when T is C(O)NH, Z is CH_2, n is 1, R^2 and R^3 are hydrogen or C_1-C_4 alkyl and Q is oxygen or sulphur, reacting a compound of formula (XIV);~~



~~wherein Hal is a suitable halogen, R^2, R^3, X^1, X^2, X^3, X^4, Z and R^6 are as defined in formula (I), with R^1OH or R^1SH in the presence of a suitable base;~~

and optionally after (a), (b), or (c), ~~(d), (e), (f), (g), (h) or (i)~~ forming a pharmaceutically acceptable salt or solvate of the compound of formula (I) obtained.

7. (Presently amended) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as ~~claimed~~ in ~~any one of claims~~ claim 1 ~~to 4~~ in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

8. (Presently amended) A process for the preparation of a pharmaceutical composition as claimed in claim 7 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as ~~claimed~~ in ~~any one of claims~~ claim 1 ~~to 4~~ with a pharmaceutically acceptable adjuvant, diluent or carrier.

9-10. (Cancelled)

11. (Presently Amended) A method of treating ~~an inflammatory disease~~asthma in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or solvate thereof, or a solvate of a salt thereof, ~~as defined claim 10.~~



(I)

wherein

Z is CR^4R^5, wherein R^4 and R^5 are CH_2;

R^1 represents a 3- to 14-membered saturated or unsaturated ring system which comprises up to two ring carbon atoms that form carbonyl groups and which further comprises up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, wherein the ring system is optionally substituted by one or more substituents independently selected from: halogen, cyano, nitro, oxo, hydroxyl, C_1-C_8 alkyl, C_1-C_6 hydroxyalkyl, C_1-C_6 haloalkyl, C_{1-6} alkoxy(C_1-C_6 alkyl), C_3-C_7 cycloalkyl(C_1-C_6 alkyl), C_1-C_6 alkylthio(C_1-C_6 alkyl), C_1-C_6 alkylcarbonyloxy(C_1-C_6 alkyl), C_1-C_6 alkylS(O)$_2$(C_1-C_6 alkyl), aryl(C_1-C_6 alkyl), heterocyclyl(C_1-C_6 alkyl), arylS(O)$_2$(C_1-C_6 alkyl), heterocyclylS(O)$_2$(C_1-C_6 alkyl), aryl(C_1-C_6 alkyl)S(O)$_2$, heterocyclyl(C_1-C_6 alkyl)S(O)$_2$, C_2-C_6 alkenyl, C_1-C_6 alkoxy, carboxy-substituted C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 hydroxyalkoxy, C_1-C_6 alkylcarboxy-substituted C_1-C_6 alkoxy, aryloxy, heterocyclyloxy, C_1-C_6 alkylthio, C_3-C_7 cycloalkyl(C_1-C_6 alkylthio), C_2-C_6 alkynylthio, C_1-C_6 alkylcarbonylamino, C_1-C_6 haloalkylcarbonylamino, SO_3H, $-NR^7R^8$, $-C(O)NR^{23}R^{24}$, $S(O)_2NR^{18}R^{19}$, $S(O)_2R^{20}$, $R^{25}C(O)$, carboxyl, C_1-C_6 alkoxycarbonyl, aryl and heterocyclyl; wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by one or more of halogen, oxo, hydroxy, nitro, cyano, C_1-C_6 alkyl, C_1-C_6 haloalkyl, phenyl(C_1-C_6 alkyl), C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, S(O)$_2$(C_1-C_6 alkyl), C(O)NH_2, carboxy or C_1-C_6 alkoxycarbonyl;

m is 0;

n is 2;

each R^2 and R^3 independently represents a hydrogen atom or a C_1-C_4 alkyl group, or $(CR^2R^3)_n$ represents C_3-C_7 cycloalkyl optionally substituted by C_1-C_4 alkyl;

T represents a group $C(O)NR^{10}$;

X^1, X^2, X^3 and X^4 are, independently, CH_2;

R^4 and R^5 each independently represent a hydrogen atom or a C_1-C_4 alkyl group;

R^6 is phenyl optionally substituted by one or more of: halogen, cyano, nitro, oxo, hydroxyl, C_1-C_8 alkyl, C_1-C_6 hydroxyalkyl, C_1-C_6 haloalkyl, C_{1-6} alkoxy(C_1-C_6 alkyl), C_3-C_7 cycloalkyl(C_1-C_6 alkyl), C_1-C_6 alkylthio(C_1-C_6 alkyl), C_1-C_6 alkylcarbonyloxy(C_1-C_6 alkyl), C_1-C_6 alkylS$(O)_2$(C_1-C_6 alkyl), aryl(C_1-C_6 alkyl), heterocyclyl(C_1-C_6 alkyl), arylS$(O)_2$(C_1-C_6 alkyl), heterocyclylS$(O)_2$(C_1-C_6 alkyl), aryl(C_1-C_6 alkyl)S$(O)_2$, heterocyclyl(C_1-C_6 alkyl)S$(O)_2$, C_2-C_6 alkenyl, C_1-C_6 alkoxy, carboxy-substituted C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 hydroxyalkoxy, C_1-C_6 alkylcarboxy-substituted C_1-C_6 alkoxy, aryloxy, heterocyclyloxy, C_1-C_6 alkylthio, C_3-C_7 cycloalkyl(C_1-C_6 alkylthio), C_3-C_6 alkynylthio, C_1-C_6 alkylcarbonylamino, C_1-C_6 haloalkylcarbonylamino, SO_3H, $-NR^{16}R^{17}$, $-C(O)NR^{21}R^{22}$, $S(O)_2NR^{13}R^{14}$, $S(O)_2R^{15}$, $R^{26}C(O)$, carboxyl, C_1-C_6 alkoxycarbonyl, aryl and heterocyclyl; wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by one or more of halogen, nitro, cyano, C_1-C_6 alkyl, C_1-C_6 haloalkyl, phenyl(C_1-C_6 alkyl), C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, $S(O)_2(C_1$-C_6 alkyl), $C(O)NH_2$, carboxy or C_1-C_6 alkoxycarbonyl;

R^7, R^8, R^9, R^{10}, R^{11}, R^{13}, R^{14}, R^{16}, R^{17}, R^{18}, R^{19}, R^{21}, R^{22}, R^{23} and R^{24} are, independently hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkyl(C_1-C_4 alkyl) or phenyl(C_1-C_6 alkyl); and,

R^{15} and R^{20} are, independently, C_1-C_6 alkyl, C_1-C_6 hydroxyalkyl, C_3-C_6 cycloalkyl, C_3-C_7 cycloalkyl(C_1-C_4 alkyl) or C_1-C_6 alkyl optionally substituted by phenyl;

R^{25} and R^{26} are, independently, C_1-C_6 alkyl or phenyl (optionally substituted by one or more of halogen, nitro, cyano, C_1-C_6 alkyl, C_1-C_6 haloalkyl, phenyl(C_1-C_6 alkyl), C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, $S(O)_2(C_1$-C_6 alkyl), $C(O)NH_2$, carboxy or C_1-C_6 alkoxycarbonyl).